{"entity":{"id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","aka":[],"tldr":"A phase 1/2 trial of TBI-1501 in acute lymphoblastic leukaemia, run by Takara Bio Inc., active and no longer recruiting.","summary":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT03155191 by Takara Bio Inc., with 21 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2035-03-31. Interventions recorded: TBI-1501.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03155191","url":"https://clinicaltrials.gov/study/NCT03155191"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["tbi-1501"],"companies":["takara-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03155191","phase":"1/2","setting":"A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia","sponsor":"Takara Bio Inc.","enrolled":21,"outcomes":[]},"route":"/trials/nct03155191/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/"}],"company":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/"}]}}